Holen Sie sich die Stockscreener-App
8.64
0.93%
0.08
Handel nachbörslich:
8.64
Schlusskurs vom Vortag:
$8.56
Offen:
$8.48
24-Stunden-Volumen:
4,447
Relative Volume:
0.03
Marktkapitalisierung:
$7.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0325
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
-6.49%
1M Leistung:
-37.25%
6M Leistung:
+8.82%
1J Leistung:
-97.54%
1-Tages-Spanne:
$8.48
$8.80
1-Wochen-Bereich:
$8.48
$9.4315
52-Wochen-Spanne:
$6.1478
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.64 | 7.85M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
Is TransCode Therapeutics Inc. stock a contrarian buyRecession Risk & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics, Inc. (RNAZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MSN Money - MSN
Real time breakdown of TransCode Therapeutics Inc. stock performanceEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
TransCode Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Will TransCode Therapeutics Inc. stock outperform value stocks2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Why retail investors favor TransCode Therapeutics Inc. stockWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Market reaction to TransCode Therapeutics Inc.’s recent news - newser.com
TransCode Therapeutics appoints Michel Janicot as development officer By Investing.com - Investing.com Nigeria
TransCode Therapeutics appoints Michel Janicot as development officer - Investing.com India
Transcode Therapeutics expands executive team with appointment of Dr. Michel Janicot as Senior Development Officer - MarketScreener
Transcode Therapeutics Expands Executive Team With Appointment Of Dr. Michel Janicot As Senior Development Officer - TradingView
TransCode Appoints Dr. Michel Janicot Senior Development Officer | RNAZ Stock News - Stock Titan
Is a relief rally coming for TransCode Therapeutics Inc. holders2025 Earnings Surprises & Capital Efficiency Focused Strategies - newser.com
Goldman Sachs Group Inc Significantly Reduces Holdings in TransCode Therapeutics Inc - GuruFocus
TransCode Therapeutics Inc. (RNAZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Using Python tools to backtest TransCode Therapeutics Inc. strategies2025 Retail Activity & Real-Time Volume Triggers - newser.com
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):